EXAI vs. CABA, KYTX, NVAX, HUMA, PRME, VALN, PROK, HLVX, ALEC, and ALLO
Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX), Novavax (NVAX), Humacyte (HUMA), Prime Medicine (PRME), Valneva (VALN), ProKidney (PROK), HilleVax (HLVX), Alector (ALEC), and Allogene Therapeutics (ALLO). These companies are all part of the "biological products, except diagnostic" industry.
Cabaletta Bio (NASDAQ:CABA) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Exscientia had 26 more articles in the media than Cabaletta Bio. MarketBeat recorded 27 mentions for Exscientia and 1 mentions for Cabaletta Bio. Exscientia's average media sentiment score of 0.49 beat Cabaletta Bio's score of 0.09 indicating that Cabaletta Bio is being referred to more favorably in the media.
Cabaletta Bio has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Cabaletta Bio received 66 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 69.44% of users gave Cabaletta Bio an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
Cabaletta Bio has higher earnings, but lower revenue than Exscientia. Cabaletta Bio is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.
41.6% of Exscientia shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cabaletta Bio currently has a consensus price target of $34.33, indicating a potential upside of 184.22%. Exscientia has a consensus price target of $9.75, indicating a potential upside of 108.33%. Given Exscientia's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Exscientia.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -737.10%. Cabaletta Bio's return on equity of -36.44% beat Exscientia's return on equity.
Summary
Cabaletta Bio beats Exscientia on 10 of the 17 factors compared between the two stocks.
Get Exscientia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exscientia Competitors List
Related Companies and Tools
